Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$62.35

0.87 (1.42%)

, HUM

Humana

$176.61

-1.19 (-0.67%)

11:37
10/06/16
10/06
11:37
10/06/16
11:37

Duchenne muscular dystrophy parent says Sarepta drug being covered by Humana

A move into positive ground for Sarepta Therapeutics (SRPT) has coincided with the circulation of a tweet from Jenn Mcnary, who identifies herself as "fighting duchenne to save my sons" in her Twitter profile. The tweet claims that Humana Insurance (HUM) "has approved 100% coverage for a patient wanting access" to Sarepta's Exondys51. Sarepta shares, which had been in negative territory earlier in the session, have moved up 15c to $62.50 at time of writing. Reference Link

SRPT

Sarepta

$62.35

0.87 (1.42%)

HUM

Humana

$176.61

-1.19 (-0.67%)

  • 06

    Nov

SRPT Sarepta
$62.35

0.87 (1.42%)

09/28/16
09/28/16
NO CHANGE

Experts 'fairly upbeat' on Sarepta drug, says RBC Capital
After speaking with three neurologists who treat DMD, RBC Capital analyst Simos Simeonidis says that the doctors were "fairly bullish" on Sarepta's DMD treatment, EXONDYS 51. The doctors expect to use the drug "in essentially all eligible patients," according to the analyst. Simeonidis raised the price target on Sarepta to $108 from $83 and keeps an Outperform rating on the stock.
09/28/16
JMPS
09/28/16
NO CHANGE
JMPS
Street underestimating price of Sarepta drug, says JMP Securities
JMP Securities analyst Liisa Bayko expects the price of Sarepta's Exondys 51 drug will be above the company's projected annual net price of $300,000. She thinks that the price will come in "closer to $538,000 per year on a gross basis, $457,000 net of discounts and compliance." The analyst raised her price target on the shares to $90 from $60 and keeps an Outperform rating on the stock.
10/04/16
PIPR
10/04/16
NO CHANGE
Target $68
PIPR
Overweight
Piper Jaffray ups Sarepta target to $68 on Summit deal
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics (SRPT) to $68 from $64 after the company licensed Summit Therapeutics' (SMMT) ezutromid to treat Duchenne Muscular Dystrophy in Europe, Turkey and the Commonwealth of Independent States. The deal is a smart way for Sarepta to capitalize on its lead in DMD with the recent FDA approval of Exondys51, Tenthoff tells investors in an intraday research note. His new price target of $68 reflects the value of ezutromid. Tenthoff reiterates an Overweight rating on Sarepta. The stock is up 1% to $61.61 in late morning trading. Summit is up 94%, or $8.17, to $16.82.
10/05/16
ADAM
10/05/16
NO CHANGE
Target $28
ADAM
Buy
Summit Therapeutics price target raised to $28 from $14 at Canaccord
Canaccord analyst Arinda Lee raised her price target on Summit Therapeutics (SMMT) to $28 from $14 following the announcement of its collaboration and licensing agreement with Sarepta Therapeutics (SRPT). The deal calls for Sarepta to gain EU commercialization rights to Summit's pipeline of oral utrophin modulators for all patients with Duchenne muscular dystrophy. Lee reiterated her Buy rating Summit Therapeutics shares.
HUM Humana
$176.61

-1.19 (-0.67%)

07/22/16
COWN
07/22/16
NO CHANGE
Target $160
COWN
Outperform
Cigna has greatest upside should DOJ block mergers, says Cowen
Cowen noted the DOJ tone toward the pending managed care deals is decidedly negative and raised the burden of proof on the companies to demonstrate the deals are not anti-competitive. Cowen believes Cigna has the most upside of the four companies involved whether the deals go through or not. Cowen has an Outperform rating and $160 price target on Cigna shares.
08/22/16
LEER
08/22/16
NO CHANGE
LEER
Leerink less positive that Anthem challenge to DOJ lawsuit will be successful
Following a conference call with an anti-trust specialist, Leerink analyst Ana Gupte is less positive that the Anthem (ANTM) challenge to the lawsuit by the DOJ will be successful. The analyst says that the specialist views the obstacles to a defense by Anthem-Cigna (CI) to the anti-trust concerns as too numerous to result in a successful close. Further, the analyst believes that any favorable decision, however unlikely, on the merger close, will likely be appealed by the DOJ. Nonetheless, the lower likelihood of this defense being successful may improve the odds of a successful Aetna (AET)-Humana (HUM) defense, the analyst notes.
08/25/16
COWN
08/25/16
NO CHANGE
COWN
Managed Care mergers unlikely to close, says Cowen
Cowen analyst Christine Arnold believes the current managed care mergers including Aetna (AET) and Humana (HUM) and Anthem (ANTM) and Cigna (CI) are unlikely to close. The analyst said the government's ability to appeal could extend the litigation process beyond the termination dates stipulated in the merger agreements. Arnold believes the Aetna/Humana merger has a better chance of closing relative to the Anthem/Cigna deal, but believes neither are likely to close.
09/22/16
EVER
09/22/16
INITIATION
EVER
Buy
Humana initiated with a Buy at Evercore ISI

TODAY'S FREE FLY STORIES

AXP

American Express

$79.71

0.2 (0.25%)

, MAT

Mattel

$26.10

0.43 (1.68%)

04:55
02/19/17
02/19
04:55
02/19/17
04:55
Conference/Events
Toy Industry Association to hold fair »

International Toy Fair…

AXP

American Express

$79.71

0.2 (0.25%)

MAT

Mattel

$26.10

0.43 (1.68%)

HAS

Hasbro

$98.50

0.86 (0.88%)

COST

Costco

$175.86

0.11 (0.06%)

AMZN

Amazon.com

$845.07

0.93 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 28

    Feb

  • 14

    Mar

  • 19

    Mar

  • 28

    Mar

QUNR

Qunar

$30.88

-0.14 (-0.45%)

15:28
02/18/17
02/18
15:28
02/18/17
15:28
Conference/Events
Qunar to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

REG

Regency Centers

$69.75

0.23 (0.33%)

, EQY

Equity One

$31.29

0.16 (0.51%)

15:21
02/18/17
02/18
15:21
02/18/17
15:21
Conference/Events
Equity One to host special shareholder meeting »

Special Shareholder…

REG

Regency Centers

$69.75

0.23 (0.33%)

EQY

Equity One

$31.29

0.16 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

EQY

Equity One

$31.29

0.16 (0.51%)

, REG

Regency Centers

$69.75

0.23 (0.33%)

15:18
02/18/17
02/18
15:18
02/18/17
15:18
Conference/Events
Regency Centers to host special shareholder meeting »

Special Shareholder…

EQY

Equity One

$31.29

0.16 (0.51%)

REG

Regency Centers

$69.75

0.23 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$7.05

0.03 (0.43%)

, ELNK

EarthLink

$5.63

-0.01 (-0.18%)

15:12
02/18/17
02/18
15:12
02/18/17
15:12
Conference/Events
EarthLink to host special shareholder meeting »

Special Shareholder…

WIN

Windstream

$7.05

0.03 (0.43%)

ELNK

EarthLink

$5.63

-0.01 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 01

    Mar

  • 06

    Mar

ELNK

EarthLink

$5.63

-0.01 (-0.18%)

, WIN

Windstream

$7.05

0.03 (0.43%)

15:09
02/18/17
02/18
15:09
02/18/17
15:09
Conference/Events
Windstream to host special shareholder meeting »

Virtual Special…

ELNK

EarthLink

$5.63

-0.01 (-0.18%)

WIN

Windstream

$7.05

0.03 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 06

    Mar

HNR

Harvest Natural

14:50
02/18/17
02/18
14:50
02/18/17
14:50
Conference/Events
Harvest Natural to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PH

Parker-Hannifin

$153.89

-0.52 (-0.34%)

, CLC

Clarcor

14:30
02/18/17
02/18
14:30
02/18/17
14:30
Conference/Events
Clarcor to host special shareholder meeting »

Special Shareholder…

PH

Parker-Hannifin

$153.89

-0.52 (-0.34%)

CLC

Clarcor

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

AZN

AstraZeneca

$29.16

0.4 (1.39%)

, BAYRY

Bayer

$113.29

0.05 (0.04%)

04:55
02/18/17
02/18
04:55
02/18/17
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2017 Genitourinary…

AZN

AstraZeneca

$29.16

0.4 (1.39%)

BAYRY

Bayer

$113.29

0.05 (0.04%)

BMY

Bristol-Myers

$54.59

0.31 (0.57%)

ESALY

Eisai

$54.40

0.205 (0.38%)

EXEL

Exelixis

$23.12

0.47 (2.08%)

GHDX

Genomic Health

$29.11

0.61 (2.14%)

MRK

Merck

$65.39

0.13 (0.20%)

MYGN

Myriad Genetics

$18.62

1.35 (7.82%)

NVS

Novartis

$77.20

0.47 (0.61%)

OPK

OPKO Health

$8.81

0.06 (0.69%)

PFE

Pfizer

PGNX

Progenics

$10.62

0.08 (0.76%)

SNY

Sanofi

$43.16

-0.38 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 27

    Feb

  • 01

    Mar

  • 02

    Mar

  • 08

    Mar

  • 09

    Mar

  • 15

    Mar

  • 17

    Mar

  • 23

    Mar

  • 29

    Mar

  • 01

    Apr

  • 10

    May

  • 27

    May

  • 14

    Jun

  • 26

    Jun

MDT

Medtronic

$78.88

0.89 (1.14%)

, NVO

Novo Nordisk

$35.46

0.02 (0.06%)

04:55
02/18/17
02/18
04:55
02/18/17
04:55
Conference/Events
Kenes International Organizers to hold a conference »

10th International…

MDT

Medtronic

$78.88

0.89 (1.14%)

NVO

Novo Nordisk

$35.46

0.02 (0.06%)

RHHBY

Roche

$30.53

0.02 (0.07%)

ABT

Abbott

$44.69

0.49 (1.11%)

SNY

Sanofi

$43.16

-0.38 (-0.87%)

LLY

Eli Lilly

$80.39

0.35 (0.44%)

DXCM

Dexcom

$81.89

0.5 (0.61%)

JNJ

Johnson & Johnson

$118.86

0.78 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 24

    Feb

  • 24

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 06

    Mar

  • 07

    Mar

  • 09

    Mar

  • 17

    Mar

  • 21

    Mar

  • 27

    Mar

  • 29

    Mar

  • 19

    Apr

  • 26

    Jun

AXP

American Express

$79.71

0.2 (0.25%)

, MAT

Mattel

$26.10

0.43 (1.68%)

04:55
02/18/17
02/18
04:55
02/18/17
04:55
Conference/Events
Toy Industry Association to hold fair »

International Toy Fair…

AXP

American Express

$79.71

0.2 (0.25%)

MAT

Mattel

$26.10

0.43 (1.68%)

HAS

Hasbro

$98.50

0.86 (0.88%)

COST

Costco

$175.86

0.11 (0.06%)

AMZN

Amazon.com

$845.07

0.93 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 28

    Feb

  • 14

    Mar

  • 19

    Mar

  • 28

    Mar

PKY

Parkway

$21.58

0.08 (0.37%)

18:20
02/17/17
02/17
18:20
02/17/17
18:20
Hot Stocks
Parkway to sell 49% interest in Houston Greenway portfolio for $512.1M »

Parkway announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 01

    Mar

VIA

Viacom

$47.00

-0.2 (-0.42%)

, VIAB

Viacom

$43.99

-0.17 (-0.38%)

18:15
02/17/17
02/17
18:15
02/17/17
18:15
Periodicals
Paramount CEO Brad Grey to leave studio as early as next week, Reuters says »

Brad Grey, chairman and…

VIA

Viacom

$47.00

-0.2 (-0.42%)

VIAB

Viacom

$43.99

-0.17 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

MNTA

Momenta

, PFE

Pfizer

18:03
02/17/17
02/17
18:03
02/17/17
18:03
Hot Stocks
Momenta: Sandoz partner Pfizer receives FDA warning letter »

Momenta Pharmaceuticals…

MNTA

Momenta

PFE

Pfizer

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 02

    Mar

  • 09

    Mar

  • 17

    Mar

  • 23

    Mar

  • 01

    Apr

CI

Cigna

$143.56

-1.77 (-1.22%)

, ANTM

Anthem

$160.25

-3.52 (-2.15%)

17:53
02/17/17
02/17
17:53
02/17/17
17:53
Periodicals
Cigna claims Anthem attempted to harm its business, Bloomberg says »

Cigna (CI) has accused…

CI

Cigna

$143.56

-1.77 (-1.22%)

ANTM

Anthem

$160.25

-3.52 (-2.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCMP

Sucampo

$11.80

0.05 (0.43%)

, NILE

Blue Nile

17:50
02/17/17
02/17
17:50
02/17/17
17:50
Hot Stocks
Sucampo to replace Blue Nile in the S&P 600 as of February 23 open »

Sucampo Pharmaceuticals…

SCMP

Sucampo

$11.80

0.05 (0.43%)

NILE

Blue Nile

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

VRML

Vermillion

$1.75

0.08 (4.79%)

17:39
02/17/17
02/17
17:39
02/17/17
17:39
Hot Stocks
Jack Schuler raises stake in Vermillion to 19.6% »

As of the date hereof,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SITO

SITO Mobile

$2.29

0.08 (3.62%)

17:34
02/17/17
02/17
17:34
02/17/17
17:34
Hot Stocks
SITO Mobile announces Jerry Hug resigned as CEO, names O'Connell interim »

Effective February 1,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 29

    Mar

CEMI

Chembio Diagnostics

$6.05

0.05 (0.83%)

17:32
02/17/17
02/17
17:32
02/17/17
17:32
Hot Stocks
Breaking Hot Stocks news story on Chembio Diagnostics »

ARS Investment Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTX

BioTime

17:31
02/17/17
02/17
17:31
02/17/17
17:31
Hot Stocks
Broadwood raises stake in BioTime to 24.5% »

Broadwood Partners,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

AHP

Ashford Hospitality Prime

$13.39

0.19 (1.44%)

17:30
02/17/17
02/17
17:30
02/17/17
17:30
Hot Stocks
Breaking Hot Stocks news story on Ashford Hospitality Prime »

Sessa Capital cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

HIIQ

Health Insurance Innovations

17:28
02/17/17
02/17
17:28
02/17/17
17:28
Hot Stocks
Breaking Hot Stocks news story on Health Insurance Innovations »

Patrick McNamee reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

HAR

Harman

$111.01

0.03 (0.03%)

, SSNLF

Samsung

17:28
02/17/17
02/17
17:28
02/17/17
17:28
Hot Stocks
Harman holders vote to approve Samsung deal »

According to a regulatory…

HAR

Harman

$111.01

0.03 (0.03%)

SSNLF

Samsung

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 28

    Mar

TST

TheStreet

$0.81

0.01 (1.25%)

17:21
02/17/17
02/17
17:21
02/17/17
17:21
Hot Stocks
Breaking Hot Stocks news story on TheStreet »

Raging Capital cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRK

Comstock Resources

$10.10

-0.65 (-6.05%)

17:17
02/17/17
02/17
17:17
02/17/17
17:17
Hot Stocks
Carl Westcott raises stake in Comstock Resources to 8.67% from 7.13% »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.